Press Releases

Press Releases

Date Title
May 12, 2022
GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
May 05, 2022
GBT Announces New Employment Inducement Grants
May 05, 2022
GBT Announces Participation in Upcoming Investor Conferences
May 04, 2022
GBT Reports First Quarter 2022 Financial Results
Apr 28, 2022
GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
Apr 27, 2022
GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022
Apr 07, 2022
GBT Announces New Employment Inducement Grants
Mar 24, 2022
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
Mar 10, 2022
GBT Announces New Employment Inducement Grants
Mar 03, 2022
The GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community-Based Organizations
Feb 28, 2022
GBT Announces Participation in Upcoming Investor Conferences
Feb 23, 2022
GBT Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 16, 2022
GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
Feb 16, 2022
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Feb 03, 2022
GBT Announces New Employment Inducement Grants
Jan 27, 2022
Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease
Jan 10, 2022
Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States
Jan 06, 2022
GBT Announces New Employment Inducement Grants
Jan 04, 2022
GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference